Le Voyer T, Gitiaux C, Authier FJ, et al. - In this single-center retrospective study, researchers tested the safety and effectiveness of JAK inhibitors (JAKi) in juvenile dermatomyositis (JDM). The sample consisted of patients with JDM treated by JAKi with a follow-up of at least 6 months. Using PRINTO criteria and skin Disease Activity Score, proportion of clinically inactive disease (CID) within six months of JAKi initiation was assessed. Nine refractory and one new-onset patients with JDM treated with ruxolitinib (n = 7) or baricitinib (n = 3) were involved. In a subset of new-onset or refractory patients with JDM, JAKis resulted in a CID and could dramatically reverse severe muscle vasculopathy. Except for a high rate of herpes zoster infection, overall tolerance was good.